Lucid Diagnostics Inc. Common Stock (LUCD)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable advantages, honest financials, and a margin of safety. Lucid Diagnostics has a promising diagnostic idea: EsoGuard and EsoCheck for GERD patients at risk of esophageal precancer and cancer. But ideas do not pay bills. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.5M and net loss was $11.7M. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $1.3M and net loss was $13.9M. For fiscal 2025, the year ended 2025-12-31, revenue was $4.7M and net loss was $58.0M; for fiscal 2024, the year ended 2024-12-31, revenue was $4.3M and net loss was $45.5M. The company has lost money each of the last four years, so FairStock assigns no Peter Lynch category. It burned $47.2M of free cash flow over the trailing twelve months, a -38.3% FCF yield against a $123.2M market cap. At the 2026-10-13 close of $0.61, FairStock calculates P/B at 10.10, ROE at -556.27%, ROCE at -81.63%, D/E at 2.28, and Altman Z-Score at -9.37. The Piotroski F-Score is 6/9, and revenue is growing from a tiny base, but there is no durable moat yet, no profit, and no margin of safety in book value. This is a story about future adoption, not a Graham bargain today.

In plain English: Lucid Diagnostics is a small medical testing company. Its main test checks people with long-term acid reflux for a risk of esophageal cancer. The business is not yet profitable, spends much more cash than it brings in, and the stock price looks expensive compared with its accounting value, so it does not look like a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer